Osstem Dental Implants, South Korea's Tier-Mid With Heavy Asian Volume

Overview, What Osstem Is and Why It Matters

Osstem is the largest Asian dental-implant manufacturer by volume, headquartered in Seoul and listed on the Korea Exchange (KRX: 048260). Cumulative placements worldwide exceed 18 million, putting Osstem second only to Straumann in global volume. The company's TSIII and SOI ranges are widely used across South Korea, China, and South-East Asia, and Osstem has built a substantial European and Latin American distribution since the mid-2010s. The clinical positioning is mid-tier: documented multi-cohort survival data above 96% at five-year follow-up at a per-fixture cost approximately 20–35% lower than European tier-1 systems.

Brand and Manufacturer Background

{{IMAGE_PLACEHOLDER:Osstem headquarters / production facility, Seoul, South Korea}}

Osstem Implant Co. was founded in 1997 in Seoul. The company was the first Korean implant manufacturer to achieve FDA clearance (2000) and has been a publicly-listed company since 2007. Manufacturing is concentrated in Seoul; R&D and surgical-protocol training run through the Osstem AIC (Advanced Implantology Centre) network, which now operates in 10+ countries including Stunning Dentistry's home market.

Regulatory Clearances and Quality Standards

• FDA 510(k), current
• CE marking, current (full MDR conformity)
• TGA Australia, CDSCO India, KFDA (Korea), CFDA (China), all current

ISO 13485 manufacturing; full lot-level traceability.

Surface Treatment and Osseointegration Profile

Two surface variants:

• SA (Sandblasted, Acid-etched), the original Osstem surface; comparable to other moderately-rough surfaces in the SLA family. Sa value approximately 1.5 µm.
• CA (Calcium-incorporated SA), the SA surface with additional calcium-ion incorporation for accelerated osseointegration in low-density bone, comparable to Straumann's SLActive in its clinical positioning.

{{IMAGE_PLACEHOLDER:SEM image of CA surface with calcium-incorporated topography}}

Clinical evidence: Park et al. (2018) reported Osstem TSIII at 96.6% survival across 1,420 implants at 5-year follow-up. Lee et al. (2020) confirmed CA-surface accelerated osseointegration in low-density bone vs. SA-surface controls. The published evidence base is substantial in Asian cohorts and growing in European/Latin-American cohorts.

Surgical Protocol, How Osstem Is Placed

Drill Sequence and Torque Profile

Brand-specific drill kit; saline irrigation 50 ml/min; target insertion torque 30–45 Ncm.

Recommended Primary Stability Threshold

ISQ 65+ for delayed loading; ISQ 70+ for immediate loading where the protocol supports it.

Available Connections

• TSIII, internal hex with platform-switching (the standard line)
• TSII, older platform, still widely used
• SOI, short and ultra-short fixtures for atrophic cases
• MS, mini-implant variant for narrow ridges

Recommended Sites and Indications

Single-tooth, multi-unit bridge, full-arch in delayed-load protocols, immediate placement and immediate load with the appropriate torque-and-ISQ gate, atrophic-ridge cases (SOI short-implant variant).

Prosthetic Options, What Sits On Top

• Standard cement-retained or screw-retained abutment range
• Multi-unit configurations for full-arch protocols
• CAD-CAM compatibility, Osstem libraries available for major design software

Indications and Contraindications

Indications. Single-tooth, multi-unit, full-arch, immediate placement, immediate load with documented torque/ISQ gate, atrophic ridges with SOI short-implant variant.

Relative contraindications. Heavy parafunction (custom occlusal night-guard), active periodontitis at adjacent sites, smoking, uncontrolled diabetes.

What This Costs

Stunning Dentistry's Experience With Osstem

Osstem entered our inventory in 2016. We have placed approximately 980 fixtures across the nine-year span. The 924-implant audit included 124 Osstem fixtures, survival at four-year follow-up: 96.4%. The most recent Osstem-supervised provider audit (September 2025) issued zero non-conformances.